These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 23621555)

  • 1. Serum uric acid and gout: from the past to molecular biology.
    Punzi L; So A
    Curr Med Res Opin; 2013 Apr; 29 Suppl 3():3-8. PubMed ID: 23621555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond gout: uric acid and cardiovascular diseases.
    Agabiti-Rosei E; Grassi G
    Curr Med Res Opin; 2013 Apr; 29 Suppl 3():33-9. PubMed ID: 23611366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum uric acid and cardio-renal diseases.
    Ruilope LM; Pontremoli R
    Curr Med Res Opin; 2013 Apr; 29 Suppl 3():25-31. PubMed ID: 23621557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Febuxostat efficacy in allopurinol-resistant tophaceous gout.
    Uh M; Reid G
    J Clin Rheumatol; 2011 Jun; 17(4):204-6. PubMed ID: 21617552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study.
    Lin KC; Lin HY; Chou P
    J Rheumatol; 2000 Jun; 27(6):1501-5. PubMed ID: 10852278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Palo WA; Eustace D; Vernillet L; Joseph-Ridge N
    Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum uric acid and metabolic risk.
    Richette P; Perez-Ruiz F
    Curr Med Res Opin; 2013 Apr; 29 Suppl 3():9-15. PubMed ID: 23611367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to manage patients with gout.
    Bardin T; Desideri G
    Curr Med Res Opin; 2013 Apr; 29 Suppl 3():17-24. PubMed ID: 23621556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Contribution of the CoLaus study to decipher the determinants of serum uric acid].
    Bochud M; Vollenweider P; Waeber G
    Rev Med Suisse; 2011 Nov; 7(315):2142, 2144-5. PubMed ID: 22187784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
    Bruce SP
    Ann Pharmacother; 2006 Dec; 40(12):2187-94. PubMed ID: 17132810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S50-6. PubMed ID: 21654270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
    Goldfarb DS; MacDonald PA; Hunt B; Gunawardhana L
    J Rheumatol; 2011 Jul; 38(7):1385-9. PubMed ID: 21572152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kidney in hyperuricemia and gout.
    Mount DB
    Curr Opin Nephrol Hypertens; 2013 Mar; 22(2):216-23. PubMed ID: 23318701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of urate-lowering therapies: managing the risks to gain the benefits.
    Keenan RT
    Rheum Dis Clin North Am; 2012 Nov; 38(4):663-80. PubMed ID: 23137576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen.
    Lin KC; Lin HY; Chou P
    J Rheumatol; 2000 Apr; 27(4):1045-50. PubMed ID: 10782835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevalence of excess blood uric acid and gout in a sample of a rural Castillian population 40-50 years of age].
    González Buitrago JM; Arroyo A; Vega L; García Fernández N; De la Rua A; Navajo JA
    Rev Clin Esp; 1988 May; 182(9):454-8. PubMed ID: 3262892
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of gout: beyond allopurinol.
    McGill NW
    Intern Med J; 2010 Aug; 40(8):545-53. PubMed ID: 20561096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.
    Schumacher HR; Becker MA; Lloyd E; MacDonald PA; Lademacher C
    Rheumatology (Oxford); 2009 Feb; 48(2):188-94. PubMed ID: 19141576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.